Search
Flurpiridaz F-18
go.drugbank.com/drugs/DB18773Approved[A264519] Flurpiridaz F-18 is an analog of pyridaben, a mitochondrial complex 1 (MC-1) inhibitor.[L51659] … Flurpiridaz F-18 is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI), which is an imaging process used in patients with known or suspected
Prezatide copper
go.drugbank.com/drugs/DB14683InvestigationalPrezatide is a tripeptide consisting of glycine, histidine, and lysine which readily forms a complex with copper ions . Prezatide is used in cosmetic products for the skin and hair. It is known to aid wound healing and its potential appl...
Denifanstat
go.drugbank.com/drugs/DB17576InvestigationalDenifanstat is an orally bioavailable fatty acid synthase (FASN) inhibitor. Due to its antineoplastic activities, it is being investigated for various cancers.
Methadyl acetate
go.drugbank.com/drugs/DB01433ExperimentalIllicitA narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence.
Ubrogepant
go.drugbank.com/drugs/DB15328ApprovedInvestigational[L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. … [A189195] They appear to be better tolerated, do not contribute to medication overuse headaches, and carry no apparent cardiovascular risk, making them suitable for use in patients with cardiovascular
Narsoplimab
go.drugbank.com/drugs/DB16418ApprovedInvestigational[A241045, A241050] Approved by the FDA on December 24, 2025, narsoplimab-wuug is indicated for the treatment of hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) in adults
Sofpironium
go.drugbank.com/drugs/DB19325Approved[L51108,L51109] Sofpironium bromide (Sofdra) was approved by the FDA in June 2024 for the topical treatment of primary axillary hyperhidrosis.
Apronalide
go.drugbank.com/drugs/DB13221ApprovedApronalide has been withdrawn from the market in many other countries due to patient development of thrombocytopenic purpura [A174814].